Please login to the form below
sumatriptan
This page shows the latest sumatriptan news and features for those working in and with pharma, biotech and healthcare.
Lilly to buy migraine drug developer CoLucid for $960m
Current triptan migraine therapies such as sumatriptan target different 5-HT receptor subtypes, notably 1B and 1D receptors, and stimulating these leads to constriction of blood vessels in the brain as
Latest news
-
Teva suspends migraine patch on burn reports
Zecuity delivers sumatriptan across the skin by a process known as iontophoresis - in which a mild electric current is applied across the skin and helps to usher active pharmaceutical compounds into ... The AERs are puzzling because iontophoresis has
-
Teva rolls out first migraine patch in US
The new Zecuity product is a disposable patch system worn for four-hours - on the upper arm or thigh - that delivers the widely-used migraine drug sumatriptan through the skin. ... Sumatriptan is a serotonin 5-HT1 agonist that has been used for years in
-
Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal
In the last few months it has also bought NuPathe for $105m - getting hold of migraine patch Zecuity (sumatriptan) - and in June offered $600m for generic player DAVA Pharmaceuticals.
-
GSK plans to sell off older products
Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established
-
Second darapladib failure disappoints GSK
Sells Treximet to Pernix. Meanwhile, GSK has sold off another brand as it reconfigures its product portfolio, this time handing over US rights to migraine therapy Treximet (sumatriptan/naproxen) to US
More from news
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Case study: Migraine management
Eight years ago, Imigran Recovery (sumatriptan) made the switch from a ‘POM’ medication to a ‘P’ licence medicine in a bid to make it more accessible to people who experience migraines. ... 80 per cent of coverage mentioned efficacy of
-
Deal Watch table for May 2014
Asset / product acquisition. 3. Marketed sumatriptan/naproxen combination. 2013 sales $79m.
-
Deal Watch table for January 2014
148. NuPathe/ Teva. Company acquisition. Includes key product Zecuity [sumatriptan] for migraine.
-
Deal Watch table for July 2013
121. ‡Optinose / Avanir Pharmaceuticals. Licence. Breath Powered intranasal sumatriptan for migraine (p3).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Roche’s Ocrevus boasts positive long-term data in MS
- Leadership change within Bedrock Group
- Lilly starts large-scale trial of tirzepatide in diabetic heart disease
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
